122 related articles for article (PubMed ID: 19912362)
1. Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer.
Zlobec I; Günthert U; Tornillo L; Iezzi G; Baumhoer D; Terracciano L; Lugli A
Histopathology; 2009 Nov; 55(5):564-75. PubMed ID: 19912362
[TBL] [Abstract][Full Text] [Related]
2. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer.
Zlobec I; Terracciano L; Tornillo L; Günthert U; Vuong T; Jass JR; Lugli A
Gut; 2008 Oct; 57(10):1413-9. PubMed ID: 18436576
[TBL] [Abstract][Full Text] [Related]
3. Expression of standard CD44 in human colorectal carcinoma: association with prognosis.
Huh JW; Kim HR; Kim YJ; Lee JH; Park YS; Cho SH; Joo JK
Pathol Int; 2009 Apr; 59(4):241-6. PubMed ID: 19351367
[TBL] [Abstract][Full Text] [Related]
4. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression.
Zlobec I; Baker K; Minoo P; Jass JR; Terracciano L; Lugli A
Clin Cancer Res; 2008 Jan; 14(1):143-8. PubMed ID: 18172264
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD44v6 has no prognostic value in patients with colorectal cancer.
Jüngling B; Menges M; Goebel R; Wittig BM; Weg-Remers S; Pistorius G; Schilling M; Bauer M; König J; Zeitz M; Stallmach A
Z Gastroenterol; 2002 Apr; 40(4):229-33. PubMed ID: 11961731
[TBL] [Abstract][Full Text] [Related]
6. The role of vascular CXCR4 expression in colorectal carcinoma.
Ingold B; Schulz S; Budczies J; Neumann U; Ebert MP; Weichert W; Röcken C
Histopathology; 2009 Nov; 55(5):576-86. PubMed ID: 19912363
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator is a marker of aggressive phenotype and an independent prognostic factor in mismatch repair-proficient colorectal cancer.
Minoo P; Baker K; Baumhoer D; Terracciano L; Lugli A; Zlobec I
Hum Pathol; 2010 Jan; 41(1):70-8. PubMed ID: 19740518
[TBL] [Abstract][Full Text] [Related]
8. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer.
Zlobec I; Minoo P; Baumhoer D; Baker K; Terracciano L; Jass JR; Lugli A
Cancer; 2008 Feb; 112(3):495-502. PubMed ID: 18076013
[TBL] [Abstract][Full Text] [Related]
9. CD44v6 as a prognostic factor in cervical carcinoma FIGO stage IB.
Bouda J; Boudova L; Hes O; Havir M; Tempfer C; Kohlberger P; Svoboda T; Rokyta Z; Speiser P
Anticancer Res; 2005; 25(1B):617-22. PubMed ID: 15816636
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study.
Morris SF; O'Hanlon DM; McLaughlin R; McHale T; Connolly GE; Given HF
Eur J Surg Oncol; 2001 Sep; 27(6):527-31. PubMed ID: 11520083
[TBL] [Abstract][Full Text] [Related]
11. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?
Chiu CT; Chiang JM; Yeh TS; Tseng JH; Chen TC; Jan YY; Chen MF
Dig Liver Dis; 2008 Sep; 40(9):749-54. PubMed ID: 18329969
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of CD44 expression in colorectal carcinomas.
Sökmen S; Lebe B; Sarioglu S; Füzün M; Terzi C; Küpelioglu A; Ellidokuz H
Anticancer Res; 2001; 21(6A):4121-6. PubMed ID: 11911305
[TBL] [Abstract][Full Text] [Related]
14. Comparison of CD44 expression in primary tumours and metastases of colorectal cancer.
Bendardaf R; Algars A; Elzagheid A; Korkeila E; Ristamäki R; Lamlum H; Collan Y; Syrjänen K; Pyrhönen S
Oncol Rep; 2006 Oct; 16(4):741-6. PubMed ID: 16969488
[TBL] [Abstract][Full Text] [Related]
15. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
Karamitopoulou E; Zlobec I; Panayiotides I; Patsouris ES; Peros G; Rallis G; Lapas C; Karakitsos P; Terracciano LM; Lugli A
Hum Pathol; 2011 Dec; 42(12):1888-96. PubMed ID: 21664646
[TBL] [Abstract][Full Text] [Related]
16. Role of APAF-1, E-cadherin and peritumoral lymphocytic infiltration in tumour budding in colorectal cancer.
Zlobec I; Lugli A; Baker K; Roth S; Minoo P; Hayashi S; Terracciano L; Jass JR
J Pathol; 2007 Jul; 212(3):260-8. PubMed ID: 17516584
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6.
Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A
Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129
[TBL] [Abstract][Full Text] [Related]
18. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of bcl-2 in UICC stage I and III colorectal carcinoma patients: correlation with c-erbB-2, p53, ki-67, CD44, laminin and collagen IV in evaluating prognostic significance.
Zavrides H; Zizi-Sermpetzoglou A; Elemenoglou I; Papatheofanis I; Peros G; Athanasas G; Panousopoulos D
Pol J Pathol; 2006; 57(3):149-59. PubMed ID: 17219742
[TBL] [Abstract][Full Text] [Related]
20. Prediction of treatment outcome by CD44v6 after total mesorectal excision in locally advanced rectal cancer.
Peng J; Lu JJ; Zhu J; Xu Y; Lu H; Lian P; Cai G; Cai S
Cancer J; 2008; 14(1):54-61. PubMed ID: 18303484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
